Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands

European Journal of Haematology

Volumn 81, Issue 6, 2008, Pages 467-474

  Stam, Wiro B ^a   O'Sullivan, Amy K ^b   Rijnders, Bart ^c   Lugtenburg, Elly ^c   Span, Lambert F R ^d   Janssen, Jeroen J W M ^e   Jansen, Jeroen P ^f  

^a MAPI GROUP   (Netherlands)

^b i3 Global   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAPI VALUES   (United States)

Author keywords

Cost effectiveness; Fluconazole; Fungal infections; Posaconazole; Prophylaxis; The Netherlands

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NETHERLANDS; NEUTROPENIA; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; QUALITY OF LIFE; REMISSION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTIFUNGAL; COSTS AND COST ANALYSIS; FEMALE; FLUCONAZOLE; HUMANS; ITRACONAZOLE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MYCOSES; MYELODYSPLASTIC SYNDROMES; NETHERLANDS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZOLES;

EID: 56649109482     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01141.x     Document Type: Article

References (29)

1. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005 56 (Suppl. 1 i5 11.
2. Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S, Schuster SJ, Stadtmauer EA, Schuster MG. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003 36 : 9 15.
3. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005 5 : 775 85.
4. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy 116. Cancer 2005 103 : 1916 24.
5. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992 326 : 845 51.
6. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995 171 : 1545 52.
7. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. a meta-analysis of 16 randomized, controlled trials. Cancer 2000 89 : 1611 25.
8. Dixon DM, McNeil MM, Cohen ML, Gellin BG, La Montagne JR. Fungal infections: a growing threat. Public Health Rep 1996 111 : 226 35.
9. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999 29 : 239 44.
10. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001 7 : 8 24.
11. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 : 327 60.
12. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 47.
13. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 59.
14. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
15. Carroll KJ. On the use and utility of the Weibull Model in the analysis of survival data. Control Clin Trials 2003 24 : 682 701.
16. Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005 23 : 515 26.
17. Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004 8 : iii1 120.
18. Jansen JP, Meis JF, Blijlevens NM, van't Wout JW. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005 21 : 1535 46.
19. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994 3 : 95 104.
20. Z-index B.V. Z-Index Taxe: Selection of the G Standard Drug Databank. Den Haag : Z-Index B.V., 2007.
21. Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006 38 : 127 34.
22. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006 57 : 317 25.
23. 't Wout JW, Kuijper EJ, Verweij PE, Kullberg BJ. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin]. Ned Tijdschr Geneeskd 2004 148 : 1679 84.
24. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005 56 (Suppl. 1 i33 8.
25. Prentice AG, Glasmacher A, Djulbegovic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. Br J Haematol 2006 132 : 656 8.
26. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, Paul M. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007 25 : 5471 89.
27. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005 131 : 22 8.
28. de Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007 356 : 409 11.
29. Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, Willemze R, van Ineveld BM. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res 2001 10 : 187 92.